Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Read-GeneWAR:RDG 79 Days Payable is 0.00 as of Jun. 2026. GuruFocus rates WAR:RDG with a GF Score™ of 79/100 and a GF Value™ of zł6.47 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 707 Biotechnology companies, Read-Gene ranks better than 72.28% on this metric.
Read-Gene's average Accounts Payable for the
three
months ended in Jun. 2026 was zł0.00 Mil. Read-Gene's Cost of Goods Sold for the
three
months ended in Jun. 2026 was zł0.26 Mil.
Hence, Read-Gene's Days Payable for the
three
months ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Read-Gene's Days Payable or its related term are showing as below:
WAR:RDG'
s Days Payable Range Over the Past 10 Years
Min: 242.81 Med: 419.36 Max: 549.49
Current: 307.8
During the past 13 years, Read-Gene's highest Days Payable was 549.49. The lowest was 242.81. And the median was 419.36.
WAR:RDG's Days Payable is ranked better than 72.28% of 707
companies
in the Biotechnology industry
Industry Median: 111.24
vs WAR:RDG: 307.80
Read-Gene's Days Payable
declined
from Jun. 2025 (4.58) to Jun. 2026 (0.00).
It may suggest that Read-Geneaccelerated paying its suppliers.
The historical data trend for Read-Gene's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:RDG vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Read-Gene's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Read-Gene Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Read-Gene's Days Payable distribution charts can be found below:
* The bar in red indicates where Read-Gene's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Read-Gene's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Read-Gene (WAR:RDG) has a Days Payable of 0.00 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Read-Gene and its competitors. Over the past decade, Read-Gene's Days Payable has ranged from 242.81 to 549.49. According to the industry distribution chart, Read-Gene ranks #196 out of 707 companies in the Biotechnology industry, placing it in the top 27.7%.
Is Read-Gene's Days Payable too high?
Read-Gene's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 242.81 to a high of 549.49. Based on the distribution chart, Read-Gene ranks #196 out of 707 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Read-Gene has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Read-Gene's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Read-Gene ranks #196 out of 707 companies for Days Payable. This puts Read-Gene in the upper half of its industry. The industry median Days Payable is 111.24. Historically, Read-Gene's own Days Payable has ranged from 242.81 to 549.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Read-Gene and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Read-Gene's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Read-Gene stock overvalued right now?
Based on GuruFocus' analysis, Read-Gene (WAR:RDG) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.47, compared to a current price of zł5.16 — trading 20.2% below its estimated fair value. The current Days Payable is 0.00. Read-Gene's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Read-Gene (WAR:RDG), the current Days Payable is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Read-Gene (WAR:RDG) Overvalued in 2026?
Based on GuruFocus' analysis, Read-Gene stock appears to be undervalued.
The current stock price of zł5.16 is trading 20.2% below its estimated GF Value™ of zł6.47.
GuruFocus considers Read-Gene to be Modestly Undervalued.
Key valuation signals for WAR:RDG:
Days Payable: 0.00
GF Value™: zł6.47 vs. price of zł5.16 (20.2% below fair value)
No single metric tells the full story. See the WAR:RDG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
79GF Score
Get the complete analysis for WAR:RDG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RDG has been successfully added to your 
